Zydus Cadila first children Covid vaccine above 12 India

Zydus Cadila first children Covid vaccine above 12 India. On August 20, the Drug Controller General of India (DCGI) approved Zydus Cadila three-dose COVID 19 vaccine for Emergency Use Authorization (EUA). The vaccine is produced in partnership with the Department of Biotechnology. It is the world’s first DNA- based vaccine and after Bharat Biotech’s Covaxin ZyCoV-D is the second made in India vaccine which got emergency use authorization. Manufacturers said that the vaccine’s side effects will be reduced because it is a needle-free vaccine. The generic drugmaker listed as Cadila Healthcare Ltd applied for authorization of ZyCoV-D on July 1st with an efficacy rate of 66.6 percent in late-stage trials of 28000 volunteers nationwide. ZyCoV-D produces the spike protein of SARS-CoV-2 to bring out an immune system. The company said that plans to manufacture 100-120 million doses and began to store the vaccine.